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Abstract
In the present study, Fe3O4 magnetic nanoparticles were
synthesized by the coprecipitation of Fe2+ and Fe3+ ions and
used as a nanocarrier for the production of piroctone-
olamine-loaded Fe3O4 nanoparticles (Fe3O4@PO NPs). The
nanocrystalline structure of the prepared iron oxide species
was confirmed by the X-ray diffraction spectroscopy method.
Particle size distribution analysis showed that the size of
Fe3O4@PO NPs was in the range of 5–55 nm. The
magnetization curve of Fe3O4@PO NPs (with saturation
magnetization of 28.2 emu/g) confirmed its ferromagnetic
property. Loading of PO on the surface of Fe3O4 NPs
qualitatively verified by Fourier transform infrared spectrum
obtained from Fe3O4@PO NPs. Cytotoxicity studies on the
human fibrosarcoma cell line (HT-1080) revealed higher
inhibitory effect of Fe3O4@PO NPs (50% cell death [IC50] of
8.1 µg/mL) as compared with Fe3O4 NPs (IC50 of 117.1 µg/mL)
and PO (IC50 of 71.2 µg/mL) alone. In the case of human
normal fibroblast (Hs68), the viability percentage was found to
be 75% in the presence of Fe3O4@PO NPs (120 µg/mL). Gelatin
zymography showed 17.2% and 34.6% inhibition of matrix
metalloproteinase-2 (MMP-2) in the presence of Fe3O4@PO
and PO, respectively, at the same concentration of 40 µg/mL,
whereas Fe3O4 NPs did not inhibit MMP-2 at any
concentration. C© 2014 International Union of Biochemistry and
Molecular Biology, Inc. Volume 61, Number 6, Pages 676–682, 2014
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1. Introduction
Special properties of materials at nanoscale compared with
corresponding bulk materials encouraged investigators to
study the physical, chemical, and biological characteristics
of nanostructures synthesized either by physicochemical or
biological methods [1]. Among nanomaterials, Fe3O4 magnetic
nanoparticles (MNPs) received more attention because of
the large specific surface area and good superparamagnetic
property that allows them to be simply separated by applying a
magnetic field [2–4]. The application of Fe3O4 MNPs has been
well documented in the literature in various areas such as
enzyme immobilization [5], magnetic resonance imaging [6],
and targeted drug delivery [7]. Recent reports have shown that
uptaking of anticancer compounds by tumor cells could be
improved after the loading of these agents on the surface of
Fe3O4 MNPs and applying a magnetic field [8]. Furthermore, in
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FIG. 1
The chemical structure of PO.
some cases, the combination of the various agents with Fe3O4
MNPs could improve the therapeutic effect and stability of the
produced nanostructures [9, 10].
Matrix metalloproteinases (MMPs) are a major group
of enzymes involved in both normal and pathological pro-
cesses [11, 12]. The key role of these highly homologous,
zinc-containing, and calcium-dependent endopeptidases
(especially MMP-2 and MMP-9) in cancer development has
been well documented in the literature [12]. So, the investiga-
tion on compounds with potential inhibitory effect on MMPs
activity has been aimed by many studies [12, 13].
Piroctone olamine (PO; Fig. 1), the amino ethanol salt of
1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)-pyridone,
has been applied in the formulation of cosmetic products,
antidandruff shampoos, as well as hair and oral care products
[14]. The apoptotic activity of PO on human and murine
myeloma and lymphoma cell lines has been recently described
by Kim et al. [15]. Furthermore, Fukuda et al. [16] determined
the inhibitory effect of PO on the collagenolytic enzyme involved
in lesion development in root dentin.
Bearing in mind the above-mentioned points about Fe3O4
MNPs and the biological activity of PO, the production and
evaluation of the cytotoxic effect of Fe3O4 MNPs coated with
PO (Fe3O4@PO NPs) on the human fibrosarcoma (HT-1080)
cell line and the human normal fibroblast (Hs68) were aimed
in the present study. In addition, the inhibitory effect of the
prepared Fe3O4@PO NPs on the activity of MMP-2 secreted
by the HT-1080 cell line was also investigated using in vitro
gelatin zymography.
2. Materials and Methods
2.1. Materials
FeCl3·6H2O, FeSO4·4H2O, sodium hydroxide, and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) were purchased from Merck Chemicals (Darmstadt,
Germany). Fetal bovine serum (FBS), Roswell Park Memorial
Institute medium (RPMI) 1640, and antibiotics were provided
by Gibco / Life Sciences (Gran Island, NY, USA). PO was obtained
from Sigma–Aldrich (St. Louis, MO, USA). All other chemicals
and solvents were of analytical grade.
2.2. Synthesis of Fe3O4 NPs
Fe3O4 NPs were synthesized using a modified reported method
consisting of the alkalization of aqueous solution contain-
ing Fe2+ and Fe3+ ions in a deoxygenated condition [17].
Briefly, deionized water was boiled for 15 Min and then cooled
to room temperature. After deoxygenation of the reaction
medium by bubbling nitrogen gas for 1 H, FeCl3·6H2O (0.48 g)
and FeSO4·4H2O (0.25 g), which was separately dissolved in
100 mL of the deoxygenated deionized water, were mixed by
a magnet stirrer (1,000 rpm, 3 Min). Thereafter, 25 mL of
sodium hydroxide solution (0.29 M) was dropwise added to the
above-mentioned mixture while it was stirred with mechanical
agitation at 1,000 rpm. The black precipitate of the Fe3O4 NPs
appeared at this stage was washed four times with deoxy-
genated deionized water after 15 Min heating at 80 ◦C. After
separation of the resulting NPs by a magnet, the prepared NPs
were lyophilized using a freeze dryer (FD-81; Eyela, Tokyo,
Japan) and stored in a sealed container at 4 ◦C.
2.3. Preparation of Fe3O4@PO NPs
To coat PO on the surface of prepared Fe3O4 MNPs, the precip-
itation method given below was used. At first, the chloroform
solution of PO (30 mg/mL) was prepared and maintained
in a sealed container. Thereafter, Fe3O4 NPs suspension was
prepared by dispersing 100 mg Fe3O4 NPs in deionized water
(100 mL) using ultrasonication (100 W, 5 Min). Subsequently,
2 mL of PO solution was added dropwise to the suspension
of Fe3O4 NPs over a 5 Min period under continuous stirring
(300 rpm) using a laboratory magnetic stirrer. The resulting
mixture was maintained at 45 ◦C for 20 Min followed by the sep-
aration of PO-coated Fe3O4 NPs from the solution by a magnet.
Finally, the capped NPs was washed four times with deionized
water and lyophilized and stored in a sealed container at 4 ◦C.
2.4. Characterization of the NPs
The magnetic NPs were characterized using different methods
before and after the coating process. For transmission electron
microscopy (TEM), one drop of an aqueous suspension con-
taining the NPs, which previously dispersed ultrasonically, was
placed on carbon-coated copper TEM grids and dried under
an infrared lamp. Micrographs were then obtained using TEM
equipment (Zeiss 902A, South Jena, Germany) operated at an
accelerating voltage of 80 kV. Particle size distribution patterns
of prepared nanostructures were measured by laser light scat-
tering method using a Zetasizer MS2000 (Malvern Instruments,
Malvern, UK). X-ray diffraction (XRD) data of the prepared
NPs were collected on a P3000 diffractometer instrument (Rich
Seifert, NY, USA) employing Cu-Kα radiation at a voltage of
40 kV and a current of 30 mA. The magnetic properties of
Fe3O4 and Fe3O4@PO NPs were determined using a vibrating
sample magnetometer (Lakeshore, Westerville, OH, USA, 7307)
with a maximum magnetic field of 10 kOe at the room temper-
ature. For qualitative analysis of the coating process, the dried
MNPs (before and after the coating process) and PO were used
for Fourier transform infrared (FTIR) spectroscopy analysis by
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a PerkinElmer (Wellesley, MA, USA) Spectrum One instrument
at a resolution of 4 cm−1 in KBr pellets.
For quantitative analysis of the coating process, a spec-
trophotometric method was applied. At first, the standard
curve of PO was drawn by plotting the measured absorbance
at 304 nm, using a UV–visible spectrophotometer (UVD-2950;
Labomed, CA, USA), against different concentrations (2.5–
−80 µg/mL) of PO dissolved in ethanol. Thereafter, 200 mg
of the washed Fe3O4@PO NPs was dispersed and sonicated
in ethyl alcohol (50 mL), and absorbances were measured at
304 nm after the separation of the Fe3O4 NPs with a magnet. In
all absorption measurements, the ethyl alcohol subjected to the
same steps with uncoated NPs was applied as the blank. These
procedures were performed in triplicate with NPs prepared at
different days, and mean of the obtained absorbances was used
to measure the amount of the PO coated on the NPs surface.
2.5. Cytotoxicity assay
The HT-1080 cell line and the Hs68 (passages 20–25) were
purchased from the National Cell Bank of Iran, Pasteur Institute
of Iran (Tehran, Iran). The cells were maintained in RPMI 1640
medium supplemented with FBS (5%), penicillin (100 U/mL),
and streptomycin (100 µg/mL) at 37 ◦C in a CO2 incubator (5%
CO2 and 95% relative humidity). For cytotoxicity assay, cells (in
the exponential phase of growth) were seeded in 96-well tissue
culture plates at 2 × 104 cells/well for 24 H. Thereafter, various
concentrations (0–120 µg/mL) of PO-coated Fe3O4 NPs, Fe3O4
NPs, and PO were added to related wells (final volume 200 µL)
and incubated for another 24 H. In the case of the HT-1080 cell
line, the corresponding supernatants of cultured cells were then
collected and assayed for gellatinolytic activity (see Section 2.6).
Subsequently, 20 µL of RPMI 1640 medium containing 5 mg/mL
of MTT was added to each well and incubated for 3 H followed
by replacing the medium by 100 µL of dimethyl sulfoxide and
measuring the optical density of the formed purple color at
570 nm. MTT assay was performed in three replicates for each
experiment.
2.6. Zymoanalysis
Gelatin zymography was performed according to the method
of the previous study [18]. Briefly, aliquots of the treated
media (obtained from cultured media of the HT-1080 cell line;
see Section 2.5) were loaded onto an SDS-PAGE instrument
containing 2 mg/mL gelatin. Electrophoresis was carried out
under nonreducing conditions at a constant voltage of 80 V.
Thereafter, the gel was gently washed with deionized water
(two times) and then one time with Triton X-100 solution
(2.5%, v/v) to remove the applied SDS from the gel followed by
the incubation of the gel at 37 ◦C for 48 H in Tris–HCl gelatinase
activation buffer (0.1 M, pH 7.4) containing CaCl2 (10 mM).
Gel staining was performed with 0.5% Coomassie Brilliant
Blue R250 (Sigma), and the proteolysis area of MMP-2 became
visible as clear bands against a blue background after intensive
destaining. A UVI pro gel documentation system (GDS-8000,
Cambridge, UK) was employed for the quantitative evaluation
of both the surface and the intensity of the bands, based on the
gray levels. Results were compared with nontreated control
wells and expressed as the relative expression of MMP-2.
2.7. Statistical analysis
Each value was expressed as the mean ± SD. Software SPSS 15
for windows (SPSS, Chicago, IL, USA) was used for the statistical
analysis. Differences between groups were determined using
one-way analysis of variance test, and P values of less than
0.05 were considered to be significant.
3. Results and Discussion
3.1. Synthesis and analysis of NPs
Before and after the coating process, the shape and size
properties of the synthesized magnetic NPs were studied
by TEM. The TEM images of Fe3O4 NPs and Fe3O4@PO are
presented in Figs. 2a and 2b, respectively. The size distribution
histograms (Fig. 3) showed that the Fe3O4 NPs and Fe3O4@PO
NPs were in the range between 1–40 and 5–55 nm, respectively.
FIG. 2
TEM micrographs of chemically synthesized
(a) Fe3O4 NPs and (b) Fe3O4@PO NPs.
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FIG. 3
The particle size distribution histograms of Fe3O4
NPs before and after the coating process with PO.
Particles with the size of 10–15 and 15–20 nm were the most
frequent particles in Fe3O4 NPs and Fe3O4@PONPs, respectively
(Fig. 3).
Agglomeration between the NPs could be created as a
result of large surface area of the NPs and the magnetic
forces between NPs [19]. The obtained results showed that the
addition of PO on the surface of the magnetic NPs increased
the size of related nanoparticles. Such effect was previously
reported for the coating of the magnetic NPs with other organic
compound such as umbelliprenin [17].
The XRD pattern of Fe3O4@PO NPs with seven character-
istic peaks of 2θ , 30.1◦, 35.6◦, 43.3◦, 53.5◦, 57◦, 63◦, and 74◦
(Fig. 4a) confirmed that the magnetic Fe3O4@PO were success-
fully synthesized, and the coating process in the presence of PO
did not have an obvious influence on the crystalline structure
of Fe3O4 MNPs. Same results were determined in the study of
Gan et al. [20] where functionalization of Fe3O4 MNPs using
boronic acid did not affect the XRD pattern of Fe3O4 NPs.
The hysteresis curves of Fe3O4 MNPs and Fe3O4@PO
NPs obtained at room temperature (Fig. 4b) show that both
samples have an obvious ferromagnetic property. Saturation
magnetization (MS) for Fe3O4 and Fe3O4@PO NPs were found
to be 43.7 and 28.2 emu/g, respectively (Fig. 4b), which are
obviously lower than that of the bulk Fe3O4 (90 emu/g). An
increase in the Fe3O4 NPs size (as previously described) together
with the presence of PO on the surface of MNPs after the coating
process might be the probable reason for a decrease in the MS
of Fe3O4@PO NPs. Same results were reported by Wei et al.
[21], indicating that the modification of Fe3O4 surface using
oleic acid and sodium citrate led to a decrease in the MS.
FTIR measurements were applied to identify the functional
groups located on the surface of NPs (Fig. 5). In the present
study, the Fe3O4 NPs showed the characteristic absorption of
Fe–O bond at 632 cm−1 (Fig. 5a). However, Fe3O4@PO NPs
FIG. 4
(a) X-ray diffraction pattern of Fe3O4@PO NPs and
(b) magnetic hysteresis curves of Fe3O4 NPs and
Fe3O4@PO NPs obtained at room temperature.
showed main peaks at 3,000, 1,625, 1,500, 1,366, 1,190, and
627 wave numbers (cm−1) corresponded to O–H or N–H, C=O,
C=C, C–N, C–O or C–N, and Fe–O functional groups, respectively
(Fig. 5b). The presence of same strong peaks in FTIR spectrum
of PO (2,996, 1,622, 1,497, 1,366, and 1,187 cm−1; Fig. 5c)
confirmed the success of the coating process. No significant
differences were observed between FTIR spectra of the NPs
with different synthesis times (data not shown).
A quantitative analysis of the coating process showed
that each 1 mg of the coated NPs contained 50 ± 1.3 µg of
PO. This amount was determined after washing the NPs by
deionized water to remove any unbounded PO. In the study of
Khorramizadeh et al. [17] wherein umbelliprenin-coated Fe3O4
MNPs were prepared by the same method, it was found that
each milligram of coated Fe3O4 MNPs contained almost 250 µg
of umbelliprenin.
3.2. In vitro cytotoxicity study
Cancer cell line
Cytotoxic effects of Fe3O4 NPs, Fe3O4@PO NPs, and PO alone at
different concentrations were evaluated on the HT-1080 cell
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FIG. 5
FTIR spectrum of (a) Fe3O4 NPs, (b) Fe3O4@PO
NPs, and (c) PO.
line. Samples were found to have different cytotoxicities on
HT-1080 cells in a direct dose–response relationship pattern,
with the Fe3O4@PO being the most potent one (Fig. 6a). For
all concentrations, the cytotoxic effect of the Fe3O4@PO NPs
is significantly higher than Fe3O4 NPs and PO (P < 0.05).
Moreover, the required concentrations to cause 50% cell death
(IC50) were 117.1 and 71.2 µg/mL in cells treated with Fe3O4
and PO, respectively. Fe3O4@PO NPs created the same effect
(i.e., 50% cell death) at a very low concentration of 8.1 µg/mL.
In other words, the new combination of PO and Fe3O4 NPs was
significantly more potent than each compound alone (P < 0.05).
Behind the antidandruff activity of PO, the ability of this
antifungal agent for the inhibition of myeloma cell lines via
the inhibition of Wnt/beta catenin signaling pathway has been
determined by Kim et al. [15]. The IC50 of PO on myeloma
(U-266, RPMI 8226, and KMS18) and lymphoma (LAM-53 and
Raji) cell lines was found to be 179 µg/mL [15]. Obtained results
of the present study revealed IC50 of 71.2 µg/mL for PO on
the HT-1080 cell line. Literature review showed a significant
difference in biological activities of cytotoxic agents and its
Fe3O4 MNPs-conjugated form in both in vitro and in vivo
models. In other words, lower amounts of cytotoxic compounds
will be needed to produce the same antiproliferative effect
when cytotoxic agents loaded on Fe3O4 MNPs [17]. So, the
efficiency of PO in conjugation with Fe3O4 MNPs to inhibit the
HT-1080 cell line was also investigated in the present study.
The obtained results showed that the cytotoxic activity of PO
(IC50 of 71.2 µg/mL) was increased when coated on the surface
of Fe3O4 MNPs (IC50 of 8.1 µg/mL) (Fig. 6a). Same results was
reported by Khorramizadeh et al. [17] who indicated an IC50
of 9 µg/mL for umbelliprenin-coated Fe3O4 MNPs compared
with umbelliprenin (a bioactive sesquiterpene coumarin)
alone, which showed IC50 of 50 µg/mL. They ascribed such
an observation for the improvement of water solubility of
target compounds after loading on Fe3O4 MNPs [17]. A better
penetration of Fe3O4@PO NPs toward cell membrane together
with solubility improvement of PO might be the possible reason
for lower IC50 of Fe3O4@PO NPs on the HT-1080 cell line
achieved in our study.
Normal cell line
The Hs68 cell was applied to determine the cytotoxic effect of
the prepared nanostructure on normal cells. Compared with
the cancer cell line (HT-1080), all applied compounds (Fe3O4
NPs, Fe3O4@PO NPs, and PO alone) represented lower toxicity
on the Hs68 cell (Fig. 6b). At the highest concentration of
Fe3O4@PO NPs (120 µg/mL), the viability of the Hs68 cell was
found to be 75%, whereas Fe3O4 MNPs exhibited viability of
89% at the same concentration (Fig. 6b). The obtained results of
the toxicity evaluation of Fe3O4 MNPs toward normal cells have
been found to be variable. For example, in the study of Cheng
et al. [19], Fe3O4 MNPs did not show any toxic effect on Cos-7
cells (monkey kidney cells). Same results were reported by
Shundo et al. [22], indicating the 100% survival of mouse
embryonic stem cells after the exposure to Fe3O4 MNPs at
high concentration of 750 µg/mL. The obtained results of Hua
et al. [23] revealed that the prepared carrier (poly-[aniline-co-
N-(1-one-butyric acid) aniline] (SPAnH) coated on Fe3O4 cores)
680 MMP-2 inhibitory effect of Fe3O4@PO NPs
FIG. 6
The cytotoxic effect of Fe3O4 NPs, Fe3O4@PO NPs,
and PO on (a) HT-1080 cell line and (b) Hs68 cell.
Data are presented as mean ± SD.
applied for the immobilization of carmustine (a chemothera-
peutic agent used for the treatment of malignant brain tumors)
represented no cytotoxic effect on human umbilical vein en-
dothelial cells after 48 H incubation. However, the applied
fibroblast in the investigation conducted by Berry et al. [24]
was found to be completely inhibited by Fe3O4 MNPs.
3.3. Zymographic studies
MMPs form a family of more than 20 zinc-dependent pro-
teinases involved in the remodeling of extracellular matrix.
They are believed to play a critical role in various disease
states such as cancer, inflammation, and degenerative dis-
eases [25]. A strong association between the activity of MMPs,
especially MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B),
and an invasive phenotype in several tumors had been well
documented. So, the screening of MMP inhibitors (even small
molecules or peptides) as therapeutic agents in various tumors
has been targeted by many investigators [25]. Fibrosarcoma
cell lines (e.g., WEHI 164 and HT-1080) are one of the most
common cell models applied for the in vitro study of MMP-
2 and MMP-9 activity [26–28]. So, in the present study, the
inhibitory effects of the Fe3O4 NPs, Fe3O4@PO NPs, and PO
on MMP-2 activity secreted by the HT-1080 cell line were also
FIG. 7
MMP-2-inhibitory effect of Fe3O4 NPs, Fe3O4@PO
NPs, and PO on HT-1080 fibrosarcoma cell line.
examined. As illustrated in Fig. 7, the relative activity of MMP-2
in the presence of Fe3O4@PO NPs and PO (at a concentration of
40 µg/mL) decreased to 34.6% and 17.2%, respectively, whereas
only 12.8% of an initial activity of MMP-2 reduced after the
treatment of the HT-1080 cell line by the same concentration of
Fe3O4 NPs. Most of the investigated MMP inhibitors contain zinc
binding groups (ZBGs) such as hydroxamic acid in their struc-
tures, which strongly interacts with the zinc ion in the catalytic
site of an MMP [25, 29]. Such ZBGs is present in the structure of
PO (Fig. 1) and might be the possible reason for the inhibitory
activity of PO in the present investigation. Furthermore, this
probable mechanism justifies the lower MMP-2-inhibitory ac-
tivity of Fe3O4@PO NPs compared with free PO (Fig. 7) because
the accessibility of bond PO in Fe3O4@PO NPs for interacting
with ZBGs of MMP-2 was decreased.
4. Conclusions
In the present work, PO was coated on the surface of Fe3O4
MNPs synthesized by the alkalization of an aqueous medium
containing Fe2+ and Fe3+ ions, and its cytotoxic effect on the
HT-1080 cell line and Hs68 was evaluated. To sum up, the
obtained results of the cytotoxic investigation revealed that
in spite of Fe3O4@PO NPs potency to inhibit the HT-1080 cell
line, PO-loaded MNPs showed lower cytotoxicity toward normal
fibroblast cells. These results suggested that Fe3O4@PO NPs
possess a great selectivity between cancer and normal cells.
The MMP-2 inhibitory effect of Fe3O4@PO NPs (studied by
gelatin zymographic) was found to be lower than PO alone.
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